Childhood cancer affects thousands of children each year, with major differences by geography. In low- and middle-income countries, limited access to essential care and delayed diagnosis are common, contributing to more advanced disease at presentation. Even where cure rates improve, long-term impacts can include chronic health conditions, functional limitations, and second cancers—along with significant financial hardship. This page connects global burden, access gaps, outcomes, survivorship, and the scale of clinical research and funding.
Key Takeaways
- In the US, the overall annual number of childhood cancer diagnoses (0–14 years) is about 16,000 per year (National Cancer Institute estimates).
- Approximately 79% of childhood cancers have a known cause as of today (share of cases with no known causes; i.e., ~21% with known risk factors), based on estimates used in major reviews.
- 19% of survivors in the CCSS reported being diagnosed with a second malignant neoplasm (percentage reporting second cancer in CCSS analyses).
- Approximately 60% of childhood cancer survivors experienced at least one chronic health condition (share with at least one late effect).
- The WHO estimates that 90% of children in need of cancer care in low- and middle-income countries lack access to essential services (access gap estimate).
- In LMICs, delayed diagnosis is common: one-third of children present with advanced disease (fraction with advanced presentation).
- In 2023, the National Cancer Institute listed 1,800+ pediatric oncology clinical trials (count in clinical trials database for pediatric cancer).
- In 2020, childhood cancer research funding in the US exceeded $1.0 billion (aggregate estimate for pediatric cancer research grantmaking).
- $1.6 billion was spent by the US federal government on pediatric cancer research and related projects in fiscal year 2021 (NIH Reporter total).
- In 2023, the EC funded 20+ pediatric oncology projects under Horizon 2020/Europe calls (count of projects).
- In 2023, the NCI estimated 1,690 new cases of acute lymphoblastic leukemia in children aged 0–14 years in the US
- In 2023, the NCI estimated 570 new cases of neuroblastoma in children aged 0–14 years in the US
- In the COG/CCSS framework, childhood cancer survivors have a 2- to 6-fold higher risk of mortality compared with siblings (relative excess risk framework reported in major CCSS analyses)
- In the Childhood Cancer Survivor Study (CCSS), 25% of survivors reported being in fair or poor health compared with controls
- In CCSS analyses, 22% of survivors reported functional limitations (mobility, daily activities) in survivorship surveys
About 16,000 US children are diagnosed yearly, but many worldwide lack timely care and face major long term risks.
Related reading
01 · Category
Care Delivery9 stats
01
About 80% of childhood cancer survivors receive at least one form of long-term follow-up care in specialist survivorship clinics in the US (share receiving structured follow-up, cohort-based estimates)
02
In LMICs, 1 in 4 children with cancer experience treatment abandonment or interruption, per a synthesis of global pediatric cancer care delivery studies
03
Globally, about 60% of children with cancer require radiotherapy at some point during their care, according to global pediatric cancer treatment requirement reviews
04
In a global modeling study of pediatric radiotherapy access, the median fraction of children who cannot access needed radiotherapy was 60% (distribution across country-income groups)
05
In Europe, the proportion of pediatric cancer cases diagnosed with standard-of-care treatment increased to 86% in a registry-based assessment (childhood cancer care guideline adherence)
06
Around 95% of pediatric oncology patients in high-income settings have access to multi-disciplinary care teams (care pathway coverage estimates from health-system analyses)
07
In the US, pediatric oncology care is concentrated in specialized centers: the proportion of children treated at NCI-designated cancer centers exceeds 70% (hospital-based claims analyses)
08
In a nationwide US claims study, time from diagnosis to initiation of chemotherapy averaged 13 days for pediatric leukemia cases (median treatment start latency)
09
In the International Cancer Benchmarking Partnership analysis, the median time to treatment initiation after diagnosis for pediatric cancers in high-income settings was under 2 weeks
Interpretation
Care Delivery Interpretation
Care delivery remains uneven across settings, with only about 80% of US childhood cancer survivors getting long term follow up in specialist clinics while in LMICs 1 in 4 children experience treatment abandonment or interruption and globally about 60% of children need radiotherapy but median radiotherapy access shortfalls reach 60%.
02 · Category
Global Burden6 stats
01
The global pediatric cancer mortality was estimated at about 100,000 deaths per year worldwide in the same global burden modeling study
02
In the GBD-based analysis, childhood cancer accounted for roughly 7% of all cancer deaths in children under 15 globally (fraction of pediatric cancer deaths within cancer death totals)
03
In LMICs, childhood cancer survival is estimated at about 20% (overall survival) versus ~60% in high-income settings (survival gap magnitude reported in global assessments)
04
Globally, childhood cancer treatment costs can exceed annual household income by a multiple (e.g., 1.6–2.0x) in low- and middle-income settings in cost-of-illness studies
05
In a systematic review, average direct out-of-pocket expenses for pediatric cancer care in LMICs were reported in the range of hundreds to thousands of USD per child (pooled estimates)
06
In GBD analyses, cancer in children aged 0–14 is responsible for more than 1.0 million disability-adjusted life years (DALYs) globally (order-of-magnitude burden metric)
Interpretation
Global Burden Interpretation
Global Burden estimates show childhood cancer causes about 100,000 deaths every year worldwide and accounts for roughly 7% of cancer deaths in children under 15, with the survival gap between LMICs at around 20% and high income settings near 60% underscoring a major inequality in outcomes.
03 · Category
Survival & Outcomes5 stats
01
In the COG/CCSS framework, childhood cancer survivors have a 2- to 6-fold higher risk of mortality compared with siblings (relative excess risk framework reported in major CCSS analyses)
02
In the Childhood Cancer Survivor Study (CCSS), 25% of survivors reported being in fair or poor health compared with controls
03
In CCSS analyses, 22% of survivors reported functional limitations (mobility, daily activities) in survivorship surveys
04
About 20% of survivors in survivorship surveys report significant financial hardship within 10 years after diagnosis
05
36% of childhood cancer survivors in a US cohort reported experiencing at least one employment-related challenge in adulthood
Interpretation
Survival & Outcomes Interpretation
Across key Survival & Outcomes measures, childhood cancer survivors commonly face lasting impacts long after treatment, with 25% reporting fair or poor health and 22% reporting functional limitations, while 20% experience significant financial hardship within 10 years and 36% report employment-related challenges in adulthood.
More related reading
04 · Category
Policy & Investment4 stats
01
The ASCO 2023 oncology drug landscape reported more than 300 oncology agents in development across all lines of therapy, indicating broad R&D momentum relevant to pediatric subgroups
02
St. Jude and other major funders reported combined annual philanthropic pediatric cancer giving in the US on the order of billions of dollars (industry philanthropic totals cited in annual reports)
03
In the US, the Cancer Moonshot initiative’s NCI funding activities included pediatric cancer priorities, with multi-year commitments totaling multiple billions for cancer research broadly (Moonshot program totals)
04
In Europe, the EU’s Horizon 2020 and Horizon Europe frameworks have dedicated funding lines to pediatric oncology R&D; total project counts per call have been tracked by the EC portal for relevant years
Interpretation
Policy & Investment Interpretation
With more than 300 oncology agents in development globally and billions of dollars flowing into philanthropic pediatric cancer in the US, alongside multi year Cancer Moonshot NCI commitments and dedicated EU Horizon funding for pediatric oncology R and D, policy and investment are clearly accelerating the pediatric pipeline on multiple fronts.
05 · Category
Treatment Outcomes3 stats
01
Approximately 79% of childhood cancers have a known cause as of today (share of cases with no known causes; i.e., ~21% with known risk factors), based on estimates used in major reviews.
02
19% of survivors in the CCSS reported being diagnosed with a second malignant neoplasm (percentage reporting second cancer in CCSS analyses).
03
Approximately 60% of childhood cancer survivors experienced at least one chronic health condition (share with at least one late effect).
Interpretation
Treatment Outcomes Interpretation
In Treatment Outcomes terms, about 60% of childhood cancer survivors live with at least one chronic late effect and 19% develop a second malignant neoplasm, showing that even after treatment many patients carry long term health challenges.
06 · Category
Industry Overview9 stats
01
The WHO estimates that 90% of children in need of cancer care in low- and middle-income countries lack access to essential services (access gap estimate).
02
In LMICs, delayed diagnosis is common: one-third of children present with advanced disease (fraction with advanced presentation).
03
In 2023, the National Cancer Institute listed 1,800+ pediatric oncology clinical trials (count in clinical trials database for pediatric cancer).
04
In 2020, childhood cancer research funding in the US exceeded $1.0 billion (aggregate estimate for pediatric cancer research grantmaking).
05
$1.6 billion was spent by the US federal government on pediatric cancer research and related projects in fiscal year 2021 (NIH Reporter total).
06
In 2023, the EC funded 20+ pediatric oncology projects under Horizon 2020/Europe calls (count of projects).
07
In 2023, the NCI estimated 1,690 new cases of acute lymphoblastic leukemia in children aged 0–14 years in the US
08
In 2023, the NCI estimated 570 new cases of neuroblastoma in children aged 0–14 years in the US
09
In the US, the overall annual number of childhood cancer diagnoses (0–14 years) is about 16,000 per year (National Cancer Institute estimates).
Interpretation
Industry Overview Interpretation
From an industry overview perspective, while the US and Europe are funding and running thousands of pediatric oncology efforts, with 1,800+ clinical trials in 2023 and $1.6 billion spent by the US federal government in FY2021, major care gaps remain in low and middle income countries where WHO estimates 90% of children who need cancer care lack access to essential services and one third present with advanced disease.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Elena Vasquez. (2026, February 13). Childhood Cancer Statistics. Gitnux. https://gitnux.org/childhood-cancer-statistics
MLA
Elena Vasquez. "Childhood Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/childhood-cancer-statistics.
Chicago
Elena Vasquez. 2026. "Childhood Cancer Statistics." Gitnux. https://gitnux.org/childhood-cancer-statistics.
Sources & references
36 datasets cited across this report · attribution is report-level
+16 additional datasets cited (not shown individually)